Depression

Is there a way to separate the neuroplasticity and therapeutic effects from the hallucinatory and dissociative effects of traditional psychedelics?

DLX-001 is a novel neuroplastogen under development for the treatment of major depressive disorder. Learn more about the latest phase 1 data here.

Learn more about the latest research on different approaches to treatments for major depressive disorder (MDD).

Navacaprant for the treatment of major depressive disorder has failed in the phase 3 KOASTAL-1 trial.

An expert shares more about the recent data on NeuroStar advanced TMS. Learn more here.

Check out 2 new psychopharmacology innovations!

Let's look back on a year marked by advancements and ongoing challenges in psychiatry.

Post-hoc analysis of the ELEKT-D trial of ketamine and ECT for patients with treatment-resistant depression distinguishes between responders to the respective interventions.

Recent research finds that after ECT, pro-inflammatory cytokines decreased significantly, and anti-inflammatory cytokines increased in teenagers with depression.

Let’s compare treatment risks when managing mixed states.

Here are 4 means of coping with the diagnostic uncertainty of bipolar mixed states.

According to new data, NeuroStar Advanced TMS helped nearly 60% of adolescents with major depressive disorder.

The FDA has granted clearance to the Horizon Inspire transcranial magnetic stimulation system to treat major depressive disorder, obsessive-compulsive disorder, and anxious depression.

How can you distinguish bipolar mixed states? Stay tuned in this short series.

Patients who have experienced a perinatal loss are at increased risk of MDD, anxiety disorders, and trauma-related disorders.

A refined rTMS protocol, the Stanford Accelerated Intelligent Neuromodulation Therapy for major depressive disorder, shows promise in bipolar disorder.

It’s time to address adult ADHD.

Adjunctive rTMS for antidepressant nonresponders? Researchers performed a randomized comparison with current antidepressant treatment approaches.

Recent research has highlighted important functional aspects of vitamin D. Learn more here.

Baseline clinical factors and early improvement in overall and specific depressive symptoms predict response to rTMS in patients with depression.

The FDA has granted Fast Track designation to liafensine for the treatment of patients with treatment-resistant depression.

As a treatment, low-dose lithium can act like a bridge between medications and integrative approaches, supporting well-being with reduced adverse effects.

Reports of suicidality with GLP-1RA antiobesity medication are supported by analysis of WHO data, but no association is found in large population cohort study or analysis of clinical trials.

The context and timing of symptoms is critical for a timely and accurate bipolar diagnosis.

Psychedelics: we first must enlarge our knowledge of how these work, what clinical conditions should be targeted, and how different psychedelics compare to each other.